Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Everest Medicines Says Kidney Disease Therapy Effective in Asian Patients

publication date: Oct 5, 2023

Everest Medicine reported positive data for Asian patients in a Phase III study of NefIgArd, a treatment for IgA Nephropathy. Nefecon® was shown to lower circulating levels of IgA-IC IgA-containing immune complexes, which accumulate in renal tissue, triggering inflammation and scarring of the glomeruli. Nefecon® is a delayed release formulation of corticosteroid that is designed to remain intact until it reaches the lower small intestine. Everest expects a positive ruling on its China NDA for Nefecon later this year. In 2019, the company acquired greater China rights to the drug from Sweden’s Calliditas in a $121 million agreement. More details....

Stock Symbol: (HK: 1952)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital